TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01549691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: 7.5 mg before sleep, the evening before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 0.5 mg at awakening, the day of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given night before surgery and at awakening, the day of surgery
Study: NCT01155726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens with comfort additive (DACP), unmasked
Description: Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens with comfort additive (DACP), unmasked
Description: Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
Study: NCT01649583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jaw Dynasplint System
Description: Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
Study: NCT03912415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or Carboplatin)
Description: IV infusion
Study: NCT01155726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens with comfort additive (1DAVM), masked
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens with comfort additive (1DAVM), masked
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens with comfort additive (1DAVM), masked
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens with comfort additive (1DAVM), partially masked
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens with comfort additive (1DAVM), partially masked
Description: Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
Study: NCT02689856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate and lidocaine hydrochloride
Description: Hydrocortisone and lidocaine in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate and lidocaine hydrochloride
Description: Hydrocortisone and lidocaine in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Vehicle cream alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Description: hydrocortisone alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Description: hydrocortisone alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: lidocaine alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: lidocaine alone
Study: NCT02873299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 Hz rTMS of the right dorsolateral prefrontal cortex
Description: Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
Study: NCT03912415

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (or Carboplatin)
Description: IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02553915

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soybean oil placebo
Study: NCT02873299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 Hz rTMS of the right dorsolateral prefrontal cortex
Description: Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
Study: NCT04616274

Intervention type: DRUG
Intervention: Venetoclax
Description: This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
Study: NCT02880449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
Study: NCT02382510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN-157

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study: NCT01912820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green tea extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quercetin
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo prostatectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00050414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
Study: NCT00047710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
Study: NCT01946243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F18
Description: No Florbetapir F 18 will be administered in this study.
Study: NCT02553915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA 1 g/day
Description: Omega-3 fatty acid extracted from fish oil, 1 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA 2 g/day
Description: Omega-3 fatty acid extracted from fish oil, 2 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA 4 g/day
Description: Omega-3 fatty acid extracted from fish oil, 4 g/day
Study: NCT01748695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V158866
Study: NCT03578822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human urokinase
Description: Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Aspirin 300mg is taken orally at the beginning of thrombolysis.

Intervention type: DRUG
Group type: OTHER
Intervention: rhPro-UK simulation agent
Description: Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin simulation agent
Description: Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
Study: NCT04980105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)
Description: Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
Study: NCT05262322

Intervention type: DRUG
Intervention: Edoxaban
Description: This was a non-interventional, observational study. No drug was administered in this study.

Intervention type: DRUG
Intervention: Apixaban
Description: This was a non-interventional, observational study. No drug was administered in this study.
Study: NCT05262322

Intervention type: DRUG
Intervention: Rivaroxaban
Description: This was a non-interventional, observational study. No drug was administered in this study.
Study: NCT01748695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03345043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAL-339851
Description: Escalating dose levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02375750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBO and GBG
Description: Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
Study: NCT01949922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous muscle fibers into the anal sphincter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesia
Description: Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study: NCT03732144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Staff-based PA intervention
Description: After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the 'Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.

Intervention type: OTHER
Group type: OTHER
Intervention: Connect Health Curriculum Control
Description: After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
Study: NCT01968369

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tomato sauce
Description: We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study: NCT03255499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive
Description: Cognitive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive
Description: Cognitive

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Active control, including a blend of computer games, board games, quizzes, trivia
Study: NCT01968369

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tomato sauce
Description: We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
Study: NCT04388787

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stochastic resonance (SR) wraps
Description: SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance (SR) wraps
Description: SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance (SR) wraps
Description: SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
Study: NCT04202757

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: [21CFR640.30] Plasma from 18 - 25 year old volunteer donors
Description: 12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Study: NCT02961582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Neuromodulation
Description: SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Conservative Treatment
Description: The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
Study: NCT04093882

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast agent enhanced MRI using Gadovist
Description: By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast agent enhanced MRI using Gadovist
Description: By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast agent enhanced MRI using Gadovist
Description: By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.